参莲胶囊联合同步放化疗治疗中晚期非小细胞肺癌临床观察

Clinical Observation of Shenlian Capsule Combined with Concurrent Chemoradiotherapy Treating Non-Small Cell Lung Cancer in Intermediate and Advanced Stage

目的：观察参莲胶囊联合同步放化疗治疗中晚期非小细胞肺癌的近期疗效和不良反应。方法：将72例中晚期非小细胞肺癌患者随机分为对照组和试验组各36例，2组均采用同步放化疗，放疗总量64-70GY／32-35F（6-7周），且在放疗期间给予EP方案（顺铂25mg／m^2,d1-3天静脉滴注，足叶乙苷l00mg／d，d1-5天静脉滴注）化疗2周期。试验组在上述基础上配合参莲胶囊6粒／次，1日3次，连用3个月。结果：试验组的近期有效率为81％，对照组为75％，试验组放化疗不良反应明显减轻，两组有差异（P〈0．05）。结论：参莲胶囊联合同步放化疗治疗中晚期肺癌患者不良反应轻，能提高患者生存质量。

Objective ： Recent effect and side effects of Shenlian Capsule combined with concurrent chemoradiotherapy treating non-small cell lung cancer in intermediate and advanced stage were observed. Methods： 72 cases were randomly divided into treatment group and control group, 36 cases in each group. The two groups were both treated with concurrent chemoradiotherapy, the radiotherapy total dose was 64 - 70GY/ 32-35F（6~Twk） and combined with EP plan （C-DDP 25mg/m2, dl-3, iv gtt, etoposide 100mg/d, dl-5,iv gtt ）. The chemotherapy need 2 cycles. Besides, the treatment group was given Shenlian Capsule 6 granule once, three times a day, for 3 months. Results： The recent effect rate of treatment group was 81% while the control group was 75%. Side effects caused by ehemoradiotherapy in treatment group were obviously reduced, with significant difference compared with control group （P〈0.05）.Conclusion：Shenlian Capsule combined with concurrent chemoradiotherapy treating nonsmall cell lung cancer in intermediate and advanced stage can increase life quality and has few side effects.